Results 71 to 80 of about 3,710 (152)
Pulmonary CirculationThis exploratory analysis assessed whether plasma biomarkers predict the response to switching from phosphodiesterase type 5 inhibitors (PDE5is) to the soluble guanylate cyclase stimulator riociguat in patients with pulmonary arterial hypertension ...
James R. Klinger +14 more
doaj +1 more source
Inoperable chronic thromboembolic pulmonary hypertension treated with riociguat: A case study
Revista Portuguesa de Cardiologia, 2015 A 51-year-old woman presented with a one-year history of progressive dyspnea, WHO functional class III-IV and exercise-related syncope. Transthoracic echocardiography and computed tomography pulmonary angiography were performed, leading to a diagnosis of
Carlos Ortiz-Bautista +4 more
doaj +1 more source
Pulmonary Circulation, 2020 This multicenter, prospective, non-interventional study (ClinicalTrials.gov: NCT02117791) evaluated the safety and effectiveness of riociguat for chronic thromboembolic pulmonary hypertension in Japanese clinical practice, registering all patients with ...
Nobuhiro Tanabe +5 more
doaj +1 more source
Pulmonary Circulation, Volume 16, Issue 3, July 2026.ABSTRACT Chronic thromboembolic pulmonary hypertension (CTEPH) is a distinct subtype of pulmonary hypertension arising from persistent major pulmonary artery obstruction after pulmonary embolism. Pulmonary endarterectomy (PEA) remains the standard of care, but up to 40% of patients in European and US registries are inoperable; balloon pulmonary ...
Miller Giraldo‐Sandoval +25 more
wiley +1 more source
Catheterization and Cardiovascular Interventions, Volume 107, Issue 7, Page 2323-2334, June 1, 2026.ABSTRACT Background Chronic thromboembolic pulmonary disease (CTEPD) leads to chronic total occlusions (CTOs) of the pulmonary arteries in a minority of patients. Treatment of CTOs with balloon pulmonary angioplasty (BPA) may substantially improve patient hemodynamics but presents unique technical challenges and has previously been associated with a ...
Elliot J. Stein +4 more
wiley +1 more source
Respiratory Medicine Case Reports, 2020 A-71-year-old woman was diagnosed as chronic thromboembolic pulmonary hypertension (CTEPH) accompanied by essential thrombocythemia (ET) with JAK2 V617F mutation.
Tomohiro Yamaguchi +7 more
doaj +1 more source
Clinical Case Reports, Volume 14, Issue 6, June 2026.ABSTRACT Chronic thromboembolic pulmonary hypertension (CTEPH) is a rare, potentially curable form of pulmonary hypertension, with limited data in pregnancy. We describe a 37‐year‐old woman with progressive dyspnea, back pain, and cough, whose evaluation revealed severe right ventricular enlargement, high pulmonary pressures, and extensive V/Q ...
Hassan Ahangar +3 more
wiley +1 more source
Comprehensive Physiology, Volume 16, Issue 3, June 2026.In patients with pulmonary vascular diseases (PAH and CTEPH), supplemental oxygen (FiO2 0.3), compared to room air (FiO2 0.21) improved peak exercise capacity (peak V̇O2), peak sustainable exercise (V̇O2 at GET), and V̇O2 kinetics and the onset of exercise.
Shir Kadosh +6 more
wiley +1 more source
Respiratory Research, 2018 Background Riociguat is a soluble guanylate cyclase stimulator approved for pulmonary arterial hypertension (PAH) and chronic thromboembolic pulmonary hypertension (CTPEH).
Alberto M. Marra +15 more
doaj +1 more source
Riociguat increases lung tissue cGMP levels.
, 2018 Riociguat significantly increased cGMP concentration in hyperoxia-exposed rats as compared with placebo treated hyperoxic rats. *P < 0.05 compared with hyperoxia + placebo (n = 4/group).
Ronald Zambrano (5497406) +13 more
core +1 more source